This site is intended for healthcare professionals

Phase III study of Estybon fails to meet primary endpoint in higher-risk myelodysplastic syndromes.- Onconova Therapeutics

Read time: 1 mins
Last updated:16th Mar 2021
Published:25th Aug 2020
Condition: Myelodysplastic Syndromes
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest